Reports Q4 revenue $22.6M, consensus $4.28M. Revenue recognized for upfront license fees and services provided from the License and Collaboration Agreement with Acadia Pharmaceuticals for the three months ended December 31, was $22.6M, compared to $2.8M for the same period in 2023. “Recent milestones – including Breakthrough Therapy Designation, positive data supporting our Phase 3 dosing regimen and global regulatory alignment – have catalyzed the Dravet community and put us on track to initiate EMPEROR in the second quarter,” said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics (STOK). “The potential of zorevunersen to change the course of Dravet syndrome by addressing its underlying cause is becoming increasingly recognized. Our recent collaboration with Biogen brings complementary expertise in neurology and the global commercialization of high-value medicines for rare genetic diseases – expertise that will help us deliver faster for patients and maximize value. With a strong financial position, we are well-capitalized to advance through Phase 3 and prepare for launch readiness.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STOK:
- Stoke Therapeutics announces CEO transition
- Stoke Therapeutics (STOK) Q4 Earnings Cheat Sheet
- Stoke Therapeutics Partners with Biogen for Zorevunersen
- Strategic Collaboration Between Stoke Therapeutics and Biogen Fuels Buy Rating for Zorevunersen Development
- Strategic Collaboration with Biogen Boosts Stoke Therapeutics’ Financial and Market Position
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue